Abstract Transrectal ultrasound (TRUS)-guided (12-14 core) systematic biopsy of the prostate is the recommended standard for patients with suspicion of prostate cancer (PCa). Advances in imaging have led to the application of magnetic resonance imaging (MRI) for the detection of PCa with subsequent development of software-based co-registration allowing for the integration of MRI with real-time TRUS during prostate biopsy. A number of fusion-guided methods and platforms are now commercially available with common elements in image and analysis and planning. Implementation of fusion-guided prostate biopsy has now been proven to improve the detection of clinically significant PCa in appropriately selected patients.
Introduction
Transrectal ultrasound (TRUS)-guided random systematic biopsy is the diagnostic approach recommended to patients with a high suspicion for prostate cancer (PCa). This approach though systematic (based on geographic regions of the prostate) Bblindly^samples the prostate without focus on any specific lesion. Standard biopsy's inability to visualize and target prostate lesions results in sampling error. These errors lead to diagnostic uncertainty and additional biopsies, which can increase unnecessary morbidity and cost [1] . Targeted prostate biopsy is an emerging technique that utilizes high-resolution multiparametric MRI (mpMRI) and ultrasound guidance to sample MR visible lesions. Though there are no compelling prospective studies suggesting that targeted biopsies alone can supplant systematic biopsies, the addition of systematic cores does capture only a limited additional number of intermediate and high-risk cancers [2••]. The combined approach should be considered as an additional level of safety to avoid under sampling the prostate and missing clinically significant prostate cancer (CSPCa).
Standard 12-core transrectal biopsy is a familiar, cost-effective, office-based procedure, but TRUS adds little imaging information that can improve PCa detection. MpMRI improves sensitivity but adds significant up-front cost and lacks real-time imaging capabilities. An MR/US fusion-guided prostate biopsy allows clinicians to unify to the strengths of each modality resulting in an office-based biopsy platform that allows preprocedure MR information to guide sampling in real-time [3] .
Multiparametric MRI is comprised of T2-weighted (T2W), diffusion-weighted imaging (DWI) with apparent diffusion coefficient (ADC) maps, and dynamic contrast-enhanced (DCE) sequences. These provide detailed anatomic and functional imaging that improves sensitivity and the positive This article is part of the Topical Collection on Prostate Cancer predictive value of detecting CSPCa. MpMRI-based suspicion for cancer correlates with biopsy pathology [4] . As mpMRI is optimized toward higher-grade disease, it limits the detection of low-risk PCa potentially reducing overdiagnosis/treatment of indolent cancers. MpMRI, a staging MRI, differs from the Bscreening^MRI (typically without an ERC) in that staging mpMRI studies are done with an ERC where improvements in signal-to-noise ratio translate to improved fidelity of the acquired images. The additional detail provided improves on the diagnosis of extracapsular extension or seminal vesicle invasion [5, 6] . Though biparametric MRI has been suggested as a possible screening tool, the term screening for conventional mpMRI falsely implies the benefits of a screening test, which should select more patients; however, it has been demonstrated that without a coil, some lesions go undetected thus decreasing sensitivity [7•, 8] . During the procedure, with MRI data available, operators can approach targeted biopsy in three major ways.
In-bore MR-Guided Biopsy This was the first method developed for the targeting of MRI positive prostate lesions. A prebiopsy mpMRI is performed, and identified lesions are subsequently targeted, while the patient is positioned inside the MRI gantry. During the procedure, the patient is placed prone in the MRI scanner, and MR visible lesions are sampled [transrectal (most common), transperineal, or transgluteal] under MR fluoroscopy guidance using core needles. Successive MR images are taken to confirm needle placement and biopsy locations are recorded [9] . This method of targeted biopsy is highly precise. Hoeks et al. in a cohort of 265 patients (with elevated PSA and prior negative TRUS biopsy), using in-bore MRGB, had a CDR of detected 41 %, many (80 %) of which were CSPCa [10] . Despite its high precision, in-bore MRI targeted biopsy is not routinely used because it is costly, requires a lot of personnel time, specialized MRI compatible equipment, and discomfort from prone positioning. It may be particularly useful for patients in which TRUS may not be possible such as post-abdominoperineal resection [11] .
Cognitive Fusion/Visual Registration In this approach, the operator reviews the lesions on the prebiopsy mpMRI and then tries to estimate the region/location where the lesion would be found on real-time TRUS imaging. Cognitive registration does not require significant capital investment or additional training with unfamiliar software or hardware. However, as accuracy is heavily operator-dependent, it has a high propensity for errors at the distal apex or base (end-fire probes) or lateral edges (side-fire probe) of the prostate due to varying anatomic presentations on true axial MRI versus the fanned image-acquisition during TRUS [12] . This can be partially overcome by careful attention to internal fiducials such as prostatic cysts, calcifications, or other relevant anatomy seen with both imaging modalities. In the PROFUS trial in which 172 patients, in the same biopsy session, underwent software MR/US fusion, cognitive fusion, and systematic biopsy, cognitive fusion had similar CDRs (32 vs 27 % PCa, p = 0.14, and 20 vs 15 % Gleason ≥7, p = 0.05) compared to MR/US fusion [13] . Haffner et al., in a cohort of 555, showed that cognitive fusion detected more PCa compared to TRUS biopsy (69 vs 59 %, p = 0.03 PCa and 67 % vs 52 %, p = 0.001 CSPCa) [14] . The increase in CDR compared to standard biopsy could in part be due to the use of MRI as a tool for selecting men at higher risk for having PCa with MR visible lesions. However, it falls short when compared to softwarebased MRI-US fusion biopsy.
Software-Based Registration Platforms To minimize user error, maximize accuracy, and perpetuate consistency of the MRI-US workflow, software-based fusion platforms incorporate complex algorithms to register and co-display MR and TRUS images during biopsy. Additionally, the needle location in 3D space can be tracked, mapped, recorded, and stored for future reference [15] . Positive cores may be recalled as targets and resampled, such as in patients on active surveillance (AS) [16, 17] . While the software platforms address cognitive fusion shortcomings, users must become familiar with additional software and hardware.
Several software-based fusion platforms are commercially available and are the most commonly used in targeted biopsy. All fusion platforms have similar steps but differ in type of image registration (rigid versus elastic), method of needle tracking, presentation of fused MR-US images, software functionality (mapping and navigation), and route of biopsy.
Indications for Fusion Biopsy
As the adoption of fusion biopsy increases, the indications for its use are also expanding [18, 19] . A number of studies have defined a role for fusion biopsy with additional benefit provided in the following:
1. Patients with continued suspicion for prostate cancer despite a negative systematic TRUS biopsy [20, 21] [28] . These studies support the use of serial imaging and fusion biopsy in AS patients.
Image Analysis and Planning
The steps required in the workflow of fusion biopsy are presented in Fig. 1 .
Segmentation Using the T2W images, the prostate outline is contoured semiautomatically and manually adjusted where needed. The MR images with the largest diameter of each lesion are utilized to define biopsy targets and approach angles. Once the prostate outline and targets are marked out on the T2W MRI, the data is transferred to the procedure workstation. Automation by computer-aided software may help in lesion identification, but interpreter expertise is still required [29] . Some workstations allow for biopsy information to feedback and integrate with PACS enabling post-biopsy image correlation as well as feedback to the radiologist that enhances their experience in prostate mpMRI interpretation.
Image Registration Each preprocedural MRI (along with segmentation and target data) selected for fusion biopsy needs to be overlaid Bfused^to a 3D TRUS volume of the prostate constructed from a series of 2D TRUS images obtained via a Bsweep^of the TRUS probe. Fusion of MR and US images is done using two possible software registration algorithms, rigid, and elastic.
1. Rigid registration aligns both images as they are captured with manipulation of each image set limited to rotation or translation (left/right or anterior/posterior correction). Rigid registration preserves the anatomy of the prostate and lesion location. If images are suboptimally aligned due to registration error, organ/patient movement, or organ deformation (by an inflated ERC), the operator can manually compensate with manual correction, alignment of indirect internal fiducials (fixed bony points, cysts, etc.), or adjust probe pressure [30] . In cases where the TRUS prostate volume does not match the MR prostate segmentation, an elastic software algorithm can be used to force matching of the corresponding datasets. 2. Elastic registration matches corresponding point landmarks (MR and US segmented volumes). This method of image registration may lead to anatomic distortion in an attempt to create the Bperfect picture^thus sacrificing accuracy in registration of the internal architecture of the prostate in an effort to align surface contours.
Most fusion platforms are equipped with both elastic and rigid registration algorithms giving the operator the flexibility to fine-tune registration and optimize targeting. Reregistration during the procedure accounts for movement of the patient or TRUS probe pressure deformation of the prostate. Lesion target accuracy depends on how well the registration is done throughout the procedure.
Fused MR-US images can be presented to the operator in different ways depending on user preference or platform type. Some platforms have the fused images separated and displayed side-by-side or alternatively images can be overlaid atop each other.
Tracking Approaches
Tracking is the ability to, in real-time, visualize the TRUS probe position and needle advancement in a 3D space throughout the procedure. This allows the operator to navigate to image slices of interest under complete visualization. Tracking can be achieved using a combination of different software and hardware, all of which may employ different technologies.
Electromagnetic (EM) tracking: used by UroNav
(Invivo); Virtual Navigator (Esaote); Real-Time Virtual Sonography (Hitachi). This tracking approach applies Faraday's Principle, whereby current can be generated in a solenoid when placed in a continuously changing magnetic field. EM tracking has multiple additional applications in various organ systems including hepatobiliary, thoracic, and even renal interventions. [31] [32] [33] . In EM tracking, a small sensor (solenoid) attached to the TRUS probe generates current due to a sequentially changing magnetic field (generated from a magnetic field generator). The current is relayed to the computer, which converts it into a 3D image display. This type of tracking allows the operator to freely manipulate the TRUS probe with multiple degrees of freedom (DoF), a process familiar to most urologists [34] . The projection of real-time 3D images onto fused MR-US images guides the operator toward regions of interest (ROIs) as defined on preprocedure MRI. The shortcoming here is that of human error due to unsteady hands at needle deployment, which can lead to registration errors. 2. Position-encoded joints in smart robotic arms: used by Artemis (Eigen), BiopSee (Pi Medical), and BioJet (BK Ultrasound). The location of the TRUS probe in 3D space is tracked by direct attachment to the robotic arm or mechanical stepper. Angle sensors in the robotic arm joints encode and automatically relay to the computer the position of the probe and needle in 3D space. The mechanical stepper similarly tracks and automatically records by utilizing position encoders in its arm joints [35, 36] . The ultrasound images are obtained by manually rotating the probe along a fixed axis. There are 2 DoF allowed when manipulating the probe: in/out and rotation [37] . Though the steady robotic arm addresses human error and improves on the positional accuracy, its software and unconventional fixed axis TRUS movement can add to the learning curve. 3. Image-based software tracking: used by the Urostation (Koelis). This system relies on TRUS images alone (without any external tracking devices) to track the probe and biopsy needle position. Initially, a 3D anatomical TRUS reference image is created from three ultrasound volumes acquired from different positions. This panorama image is fused via elastic registration to the preprocedure MRI data [38, 39] . A 3D TRUS image is obtained, after spring-deployment and before needle retraction out of the prostate, to confirm/register needle position onto the 3D panoramic reference image as well as ensure adequate target sampling [34] . Freehand probe movement is employed.
Mapping and Navigation
Mapping is like a GPS that tracks, records, and locates (Bpins^) the biopsy specimen onto the prebiopsy MRI (Bmap^). The recorded information can be accessed and reviewed in the future when needed. Navigation is the real-time imaging feedback that guides needle location and advancing toward the ROI. A combination of tracking, mapping, and navigation provides the operator superior visualization of ROI, accurate targeting, and data archives for future use in follow-up patients. For example, should a random sextant core turn out to be positive at a location where there was no MR lesion, the mapped needle core coordinate becomes a new target point in repeat fusion biopsy [17] . reconstruction. This 3D rendering is co-registered (elastic/rigid registration) with the MRI dataset. MR-US co-registered images are co-displayed above (a) and beside (a, b) each other. 3D rendering of the prostate (with overlaid needle core location) generated after sampling and tracking. TRUS transrectal ultrasound, 2D two-dimensional, 3D three-dimensional
Biopsy Approach
Transrectal (TR) and transperineal (TP) are the two main biopsy approaches. In TR biopsy, access to the prostate is via the rectal mucosa and therefore increases the likelihood of introducing rectal flora into the bloodstream or urinary tract. The frequency of biopsy related infections varies amongst studies with reported infection rates ranging from 0 to 6.3 %. There is, however, evidence that TR patients are at an increased risk of biopsy-related urinary tract infections and sepsis compared to TP patients [40, 41] . A study of 245 TP approach patients showed 0 % rate of hospital readmission for infection [42] . The major culprit pathogens are the antibiotic (mostly fluoroquinolones)-resistant bacteria. A recent meta-analysis of 2541 patients showed a higher prevalence of fluoroquinolone-resistant bacteria in post-biopsy rectal cultures (20.4 %) than in pre-TRUS biopsy (12.8 %) rectal cultures [43] . Evaluating and developing efficient local prophylactic standard procedures may help reduce the rates of prostate biopsy-related infections [44] . TP biopsy may potentially be a reasonable alternative to patients with a history of sepsis or with significant concern for infectious complications. Though generally performed under sedation, TP biopsy under local anesthesia has been reported [45] .
Major Platforms
As earlier mentioned, there are three major fusion technologies available for prostate biopsy. It is important to note that many have and continue to evolve.
Electromagnetic Tracking
The UroNav platform (Invivo, USA) is developed via a collaborative partnership between the National Institutes of Health (NIH) and Philips Medical/Invivo Corporation. This platform has undergone extensive testing and clinical trials since its approval by the FDA in 2006. The system is designed to integrate with various ultrasound vendors (Philips, GE, and BK) as well as interface with the commonly used PACS software thus reducing cost of system acquisition. The workflow begins with a preprocedure mpMRI study. The images (T2WI, DWI, DCE) obtained are preprocessed on a separate imaging workstation (DynaCad, Invivo) by the radiologist, who segments and defines target lesions. The MR data sets are sent via network connections between the imaging workstation and the UroNav device.
During the procedure, the patient is placed decubitus on the operating table. The field generator is affixed to the operating table and adjusted to sit above and close to the pelvis of the patient. An anesthetic gel is applied in the rectum to reduce pain during TRUS probe manipulation. A few minutes after the lidocaine jelly application, the operator gently inserts a 2D TRUS probe (with an attached solenoid sensor) and performs periprostatic nerve blocks after which an initial ultrasound sweep of the prostate is done. The sweep captures small slices of the prostate, which are automatically compounded to construct a 3D TRUS prostate volume that will be segmented and registered with the corresponding MR data set [46] . Registered images are inspected and manually aligned as needed throughout the procedure [47] .
The fused MR-US images are displayed simultaneously side-by-side as well as overlaid atop each other. The freehanded TRUS probe is guided using the UroNav navigation system to the ROI. Freehand TRUS probe movement allows for several DoF creating multiple angles of approach and visualization. The needle is constantly under visualization as it is advanced toward the target. In order to adequately sample the lesion, the needle is inserted with its tip as close as possible to the lesion prior to spring deployment with cores taken in the axial and sagittal planes [48] . After the completion of the procedure, the data is then sent back to the imaging workstation to be reviewed and stored for future analysis. The UroNav system is accurate with registration/tracking error reported at 2-3 mm [49] .
The UroNav system has evolved from its original design. Initially, only rigid registration and navigation were possible, but today, elastic registration and mapping capabilities have been added, making it a more robust fusion platform. Most recently, a transperineal fusion platform has become available and is being prospectively evaluated. Fusion biopsy with UroNav has demonstrated significant benefit in prostate biopsy. In a landmark study by Siddiqui et al. in which patients underwent both fusion biopsy and standard 12-core biopsy, the UroNav fusion platform detected 30 % more high-risk cancers (Gleason score ≥4 + 3) than standard TRUS biopsy [2••]. In a phase III clinical trial, UroNav detected cancer in 72 % of high-risk lesions versus 47 % in low-risk lesions demonstrating improved detection of CSPCa [50] .
Virtual Navigator [VNav] (Esaote, Italy) and Real-Time Virtual Sonography [RVS] (Hitachi, Japan)
Like all other fusion platforms, a preprocedure MRI study is performed, prostate MRI segmented, target points defined, and data transferred to the procedure workstation. Both platforms enable real-time fusion imaging between ultrasound and a second reference imaging modality (PET/CT, MRI, 3D ultrasound) [51] . These two platforms have been more commonly used in other interventional applications, including hepatobiliary interventions [52] . The utility in prostate biopsy/ treatment is sparse with very limited data available. Miyagawa et al., in a small cohort of 85 prior negative patients, reported an RVS CDR of 62 %, higher than the reported 38-55 % in other fusion platforms [53] . VNav has also shown higher CDR than standard biopsy: 69 versus 59 %, p = 0.033 [54] . VNav utilizes rigid registration and therefore is prone to associated errors as described previously [30] . RVS utilizes both transrectal and transperineal routes of biopsy.
Mechanical Position Encoders
The Artemis (Eigen, Grass Valley, CA) Recruitment of patients started in 2009 soon after the commercial model of the Artemis was FDA cleared in 2007. The Artemis uses the independent software (Eigen ProFuse) workstation [55] . Again, the workflow and software are similar to the other platforms. The major difference is TRUS probe manipulation. The Artemis does not require an external tracking system. Instead, the endfire TRUS probe held by a mechanical robotic arm (affixed to the operating table) is tracked in 3D space by angle sensing encoded joints. The preprocedure MRI data (with targets) along with 12 preselected biopsy sites (generated by Artemis) are uploaded and aligned/fused semiautomatically to the initially constructed 3D ultrasound volume [56] . In order to maximize accuracy, biopsy cores are obtained at 3-mm intervals based on a 1.2 ± 1.1-mm tracking accuracy on repeat biopsy [57] . While this addresses the issue of unstable human hands during needle deployment, it does, however, limit the DoF of movement (along a fixed axis) of the TRUS probe.
The Artemis, like UroNav, has the ability to track and record biopsy sites, allowing the operator, to rebiopsy site of previous positive cores with a 1.2-3-mm accuracy. In a study of 106 active surveillance and 68 patients with a prior negative TRUS biopsy (with persistently increasing PSA) patients, the Artemis system was three times more likely to detect cancer than standard biopsy (21 vs 7 %) [56] .
The BiopSee platform (Pi Medical, Greece) In this platform, the TRUS probe is placed in a custom-made mechanical fixation device (the stepper) affixed to the operating table. TRUS probe movement is limited to two DoF: probe rotation and depth in/out of the rectum. Two built-in encoders track both movements and relay positional data to the computer workstation [35] . Although limited in DoF, the 0.1-mm linear and 0.1°rotational resolution allows for reproducible high accuracy imaging of the entire prostate. Unlike most platforms, the BiopSee only utilizes a transperineal approach. The BiopSee hardware set-up is similar to that used in brachy therapy; parts used in diagnosis can potentially be reused in therapy as well [58] .
The software design is modular with each procedure step mapped in a separate software module. Preprocedure MR images are segmented, lesions identified, and target points defined. During biopsy, a series of 2D ultrasound images are obtained via a cranio-caudal sweep and used to construct a 3D ultrasound volume, which is then fused with prebiopsy MRI data via rigid registration [59] . Lastly, the needles are inserted under longitudinal guidance and biopsy cores obtained transperineally [58] .
The BioJet platform is FDA approved and has its TRUS probe mounted to an angle-sensing encoded mechanical arm that exports information about the position of the probe to the workstation. This uses both the transperineal and transrectal biopsy approaches. Preprocedure MRI data is fused with 3D TRUS construct using rigid registration. During transperineal biopsy, the biopsy template coordinates are shown on the computer monitor when the operator selects a given ROI [60] . Side fire mode can be used to minimize probe deformation of the prostate. There is room for evolution of this platform as it only uses rigid registration currently [61] . Shoji et al., with the first clinical application of this platform, detected cancer in 14 of 20 (70 %) many of which were high grade with longer core lengths than standard biopsy [59] . Also, BioJet CDRs have been shown to correlate with higher Prostate Imaging Reporting and Data Systems (PIRADS) scores (positive PCa 4.0 ± 1.3 vs negative PCa 2.6 ± 0.8) [61] . Like most fusion platforms, BioJet early studies trend toward higher CDRs compared to standard biopsy.
Image-Based Tracking Platform
The Urostation platform (Koelis, France) Similar to other systems in the use of preprocedure MRI, freehand probe movement, and elastic and rigid registrations, it is currently the dominant platform utilized in Europe. The Urostation differs from the other platforms in several ways. It relies purely on 3D TRUS image tracking without any form of beam tracking external hardware.
Initially, three 3D TRUS volumes are acquired from different positions and compounded into a panoramic 3D TRUS reference volume of the prostate. An anatomical atlas is built by mapping the manually segmented pre-MRI slices onto the panoramic reference image. Image registration and fusion are elaborate processes that minimize registration errors due to probe deformation or unconscious patient movement thus improving accuracy. In other words, this platform is less sensitive to organ movement during procedure [39] .
During biopsy, 2D real-time TRUS images are used to guide the operator, but 3D TRUS is used when positional information about the targeted or collected sample is required [39] . The biopsy needle is held in situ after spring needle deployment for a minimum of 3 s [30, 34] until 3D TRUS image is taken retrospectively to locate the biopsy site. The locating TRUS image is registered onto the TRUS panorama reference image for confirmation and storage [62] .
In a preclinical study, the Urostation showed high accuracy (24/27 MR ROIs: 84 %) in targeting prostate phantom ROIs [62] and an even higher accuracy when used on patients (112/ 114 MR ROIs: 97 %) [63] .
Discussion and Conclusions
Multiparametric MRI and fusion-guided biopsy have demonstrated clinical benefit over systematic biopsy alone. The ability to co-register MRI to real-time TRUS images allows for accurate sampling of PCa leading to improved diagnosis, risk stratification, and treatment. The future of fusion biopsy technologies seems promising, significant investment in commercially available fusion platforms continues, and adoption is expanding. The challenge we face is appropriate utilization in the patient population that will benefit the most [64, 65] .
Clinical centers utilize different fusion platforms, varying selection criteria, as well as different MRI scoring systems (PIRADS, NIH suspicion score, etc.) making it difficult for head-to-head comparison of these platforms. A recent publication reported decrease in diagnostic accuracy of PIRADSv2 compared to 5-point Likert scale based on the ESUR guidelines from 2012 with each patient acting as their own control [66] . Standardized reporting is essential; however, interpretation is subjective and proposed scoring systems should reflect appropriate risk stratification with respect to the presence of CSPCa [67] . Small differences in interpretation can alter outcomes of fusion biopsy devices and make comparing systems between institutions and historical data almost impossible. The authors advise centers to record granular sequencespecific data to allow for future analyses [66] .
The benefit trends (high overall CDRs with fewer cores, detection of more high-risk than low-risk disease, increase reclassification of patients on active surveillance, extended use in focal curative therapies, etc.) of fusion biopsy are consistent and supported by peer-reviewed evidence irrespective of the fusion platform used [2••, 22, 34, 50, 68, 69] . Rather than selecting the optimal technology or device, the challenge becomes ensuring responsible and judicious utilization by individuals with the appropriate expertise and training. 
